Matthias Barz
Overview
Explore the profile of Matthias Barz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
875
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang H, Barz M
J Control Release
. 2025 Mar;
381:113559.
PMID: 40023226
Lipid nanoparticles (LNPs) are the most established and clinically advanced platform for RNA delivery. While significant efforts have been made to improve RNA delivery efficiency for improved protein production, the...
2.
Schwiertz D, Angelina J, Zhang H, Barz M
Biomacromolecules
. 2024 Sep;
25(10):6539-6554.
PMID: 39292980
Miktoarm star polymers exhibit a captivating range of physicochemical properties, setting them apart from their linear counterparts. This study devised a synthetic pathway to synthesize cationic miktoarm stars utilizing polypept(o)ides...
3.
Barz M, Parak W, Zentel R
Adv Sci (Weinh)
. 2024 Jul;
11(34):e2402935.
PMID: 38976560
This review describes the formation of a protein corona (or its absence) on different classes of nanoparticles, its basic principles, and its consequences for nanomedicine. For this purpose, it describes...
4.
Schneider P, Zhang H, Simic L, Dai Z, Schrors B, Akilli-Ozturk O, et al.
Adv Mater
. 2024 Jul;
36(41):e2404784.
PMID: 38958110
Hepatocellular carcinoma (HCC) is the most frequent type of primary liver cancer and the third leading cause for cancer-related death worldwide. The tumor is difficult-to-treat due to its inherent resistance...
5.
Bi D, Wilhelmy C, Unthan D, Keil I, Zhao B, Kolb B, et al.
Adv Healthc Mater
. 2024 Jun;
13(26):e2401252.
PMID: 38889433
Lipid nanoparticle (LNP) remains the most advanced platform for messenger RNA (mRNA) delivery. To date, mRNA LNPs synthesis is mostly performed by mixing lipids and mRNA with microfluidics. In this...
6.
Horvat N, Chocarro S, Marques O, Bauer T, Qiu R, Diaz-Jimenez A, et al.
ACS Nano
. 2024 Apr;
18(17):11025-11041.
PMID: 38626916
ALK-positive NSCLC patients demonstrate initial responses to ALK tyrosine kinase inhibitor (TKI) treatments, but eventually develop resistance, causing rapid tumor relapse and poor survival rates. Growing evidence suggests that the...
7.
Capeloa L, Miravet Marti R, Duro-Castano A, Nebot V, Barz M
Chemistry
. 2024 Apr;
30(31):e202304375.
PMID: 38563634
The clinical translation of polysarcosine (pSar) as polyethylene glycol (PEG) replacement in the development of novel nanomedicines creates a broad demand of polymeric material in high-quality making high-purity sarcosine N-carboxyanhydride...
8.
Bi D, Van Hal A, Aschmann D, Shen M, Zhang H, Su L, et al.
Small
. 2024 Mar;
20(32):e2310781.
PMID: 38488770
Improving target versus off-target ratio in nanomedicine remains a major challenge for increasing drug bioavailability and reducing toxicity. Active targeting using ligands on nanoparticle surfaces is a key approach but...
9.
Shalgunov V, Lopes van den Broek S, Andersen I, Raval N, Schafer G, Barz M, et al.
Nucl Med Biol
. 2024 Jan;
128-129:108877.
PMID: 38232579
Brain pretargeted nuclear imaging for the diagnosis of various neurodegenerative diseases is a quickly developing field. The tetrazine ligation is currently the most explored approach to achieve this goal due...
10.
Breder-Bonk C, Docter D, Barz M, Strieth S, Knauer S, Gul D, et al.
Nanomaterials (Basel)
. 2023 Sep;
13(18).
PMID: 37764575
Exposure to nanoparticles is inevitable as they become widely used in industry, cosmetics, and foods. However, knowledge of their (patho)physiological effects on biological entry routes of the human body and...